Method of inhibiting binding or activity of MIF by administering a MIF antagonist
AssigneesBaxter International Inc., Baxter Healthcare S.A.
InventorsRichard J. Bucala, Lin Leng, Christine N. Metz
Life of this patent
Estimating the term…
Abstract
Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.
Claims5
A method of inhibiting the binding of macrophage migration inhibitory factor (MIF) on a cell comprising on the cell surface a MHC class II invariant chain (Ii) polypeptide, said method comprising:
- contacting said cell in vitro with an antagonist of MIF wherein said antagonist is a recombinant polypeptide comprising a MIF protein-binding fragment of the amino acid sequence of SEQ ID NO:
- 2, thereby inhibiting the binding of MIF to said Ii polypeptide.
A method of inhibiting binding of macrophage migration inhibitory factor (MIF) to a MHC class II invariant chain (Ii) polypeptide in vitro, said method comprising:
- contacting MIF with an antagonist of MIF, wherein said antagonist of MIF is a recombinant polypeptide comprising a MIF protein-binding fragment of the amino acid sequence of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.